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Lactate dehydrogenase-5 (LDH-5) catalyses the reversible transformation of pyruvate to lactate, having a principal position in the
anaerobic cellular metabolism. Induction of LDH-5 occurs during hypoxia and LDH-5 transcription is directly regulated by the
hypoxia-inducible factor 1 (HIF1). Serum LDH levels have been correlated with poor prognosis and resistance to chemotherapy and
radiotherapy in various neoplastic diseases. The expression, however, of LDH in tumours has never been investigated in the past. In
the present study, we established an immunohistochemical method to evaluate the LDH-5 overexpression in tumours, using two
novel antibodies raised against the rat muscle LDH-5 and the human LDH-5 (Abcam, UK). The subcellular patterns of expression in
cancer cells were mixed nuclear and cytoplasmic. In direct contrast to cancer cells, stromal fibroblasts were reactive for LDH-5 only in
a minority of cases. Serum LDH, although positively correlated with, does not reliably reflect the intratumoral LDH-5 status. Lactate
dehydrogenase-5 overexpression was directly related to HIF1a and 2a, but not with the carbonic anhydrase 9 expression. Patients
with tumours bearing high LDH-5 expression had a poor prognosis. Tumours with simultaneous LDH-5 and HIF1a (or HIF2a)
overexpression, indicative of a functional HIF pathway, had a particularly aggressive behaviour. It is concluded that overexpression of
LDH-5 is a common event in non-small-cell lung cancer, can be easily assessed in paraffin-embedded material and provides important
prognostic information, particularly when combined with other endogenous markers of hypoxia and acidity.
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Rapid cancer cell proliferation and high metabolic demands,
defective structural and functional angiogenesis, as well as
irregular spatial relation between cancer cells and stromal
vasculature are the principal causes of intratumoral hypoxia
(Giatromanolaki and Harris, 2001; Vaupel et al, 2001). Reduced
oxygen tension is a well-recognised cause of failure of radio-
therapy, as reduced intracellular oxygen levels result in decreased
free radical formation during irradiation and consequently to a
lower amount of DNA strand breaks (Gray et al, 1953; Brown,
2002). Furthermore, the molecular cascade triggered in the context
of cancer cell response to the hypoxic stress establishes an
aggressive phenotype with increased metastatic potential and
resistance to various apoptotic stimuli (Rofstad, 2000; Harris,
2002).
Glycolysis is a major source for the production of ATP from
glucose, which is transformed to pyruvate while NADþ is reduced
to NADH. The fate of the pyruvate molecules produced depends on
the oxygen presence. Adequate oxygenation allows the conversion
of pyruvate to ATP, water and carbon dioxide, the reversible
transformation of which to carbonic acid is catalysed by the
enzyme carbonic anhydrase (Opavsky et al, 1996). Lack of oxygen
or biochemical defects relevant to the electron transport system or
the citric acid cycle restricts ATP production to glycolysis. The
glycolytic ATP production will continue as long as NADþ is
available, the availability of which is guaranteed if oxidation of
NADH back to NADþ is feasible. Such an oxidation occurs during
the reversible transformation of pyruvate to lactate, a reaction
catalysed by lactate dehydrogenase-5 (LDH-5) (Holbrook et al,
1975). Lactate dehydrogenase-5 is one of the five isoenzymes of the
LDH, composed of four M-subunits and has the highest efficiency
among all other isoenzymes to catalyse pyruvate transformation to
lactate. The higher the number of H-subunits the LDH contains,
the lower the ability of the enzyme to catalyse the reaction, so that
LDH-1 (composed of four H-subunits) favours the conversion of
pyruvate to acetyl-CoA that enters into the citric acid (Krebs)
cycle. Upregulation of LDH-5 by cancer cells guarantees a strong
glycolytic metabolism and reduced dependence of cells in the
presence of oxygen. The hypoxia-inducible factors 1a and 2a Received 31 March 2003; revised 12 June 2003; accepted 24 June 2003
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transcription of both LDH-5 and carbonic anhydrase 9 (CA9)
(Firth et al, 1995; Semenza et al, 1996; Ebert and Bunn, 1998;
Wykoff et al, 2001).
In the present study, we compared the overexpression of LDH-5
and CA9 in non-small-cell lung cancer (NSCLC). Increased activity
of LDH, being linked with intratumoral hypoxia and acidity
(Yamagata et al, 1998), should be related with aggressive tumour
features as shown in a previous study on CA9 in NSCLC
(Giatromanolaki et al, 2001a). As HIFas regulate glycolysis and
LDH transcription, we further assessed the HIF association with
LDH expression. The prognostic relevance of LDH in comparison
with CA9 and HIFas was also assessed.
MATERIALS AND METHODS
Archival paraffin-embedded biopsy material from 76 primary
squamous cell lung carcinomas and 36 lung adenocarcinomas were
retrieved, and 3mm tissue sections were cut on slides (Department
of Pathology, University of Oxford, UK). All patients had early
operable cancer (T1,2–N0,1 stage) and were treated with surgery
alone. Histological diagnosis, grading and N-stage were performed
on haematoxylin–eosin-stained sections.
A total of 87 patients were male and 25 female, their ages
ranging from 35 to 74 years (median 63). Survival data were
available for all 104 patients. At the time of analysis, 54 patients
out of 112 were dead, while the median follow-up of surviving
patients was 57 months (range 22–83 months).
Cancer tissue samples examined were chosen from the tumour
periphery, so that normal lung was included. Specific conditions
around the tumour (hypoxia, acidity, high growth factor
concentration) could have affected the LDH-5 expression status
in the adjacent lung. To avoid such a bias, we further assessed the
expression of LDH-5 protein in: (i) 10 tissue samples containing
normal alveolar and bronchial tissue obtained from autopsies and
(ii) 10 samples from apparently normal lung (located away from
the tumour) obtained from patients who underwent pneumonect-
omy. These samples were retreived from the archives of the
department of Pathology, Democritus University of Alexandrou-
polis, Greece.
LDH-5 immunohistochemistry
The sheep polycloncal ab9002 (Abcam, Cambridge, UK) raised
against human LDH-5 purified from human placenta, and the goat
polyclonal ab7639 (Abcam, Cambridge, UK) raised against rabbit
muscle lactate dehydrogenase were used for immunohistochem-
istry (Zaman et al, 1999). Ab9002 is an IgG fraction, the identity of
which was confirmed by double diffusion against purified LDH-5
and a known anti-human LDH-5. Specificity has been demon-
strated by Western blot against liver cell lysate. Ab9002 is available
in liquid form, in glycine-buffered saline pH 7.4, 0.1% sodium
azide, 0.1% EACA, 0.01% benzamidine and 1mM EDTA. Ab7639 is
an IgG fraction antibody purified from monospecific antiserum by
a multistep process including delipidation, salt fractionation and
ion exchange chromatography followed by extensive dialysis
against a buffer composed of 0.15 M Nacl, 0.01% sodium azide at
pH 7.2. Ab7639 is available in liquid form, in protease-free
10mgml
 1 bovin serum albumin BSA IgG and 0.01% gentamicin
sulphate.
A modified streptavidin technique was used for immunohis-
tochemistry. Following multiple experiments, the optimal concen-
tration of the Ab standardised for immunohistochemistry in
paraffin-embedded tissues was 50mgml
 1 (1:200) for both
antibodies. Sections were deparaffinised and peroxidase was
quenched with methanol and H2O2 3% for 15min. Microwaving
for antigen retrieval was used (3 5min). The primary antibody
was applied overnight. Following washing with TBS, sections were
incubated with a secondary antibody (Kwik Kit, Cat. No. 404050,
Thermo Shandon, Pittsburgh, PA 15275, USA) for 15min and
washed in TBS. Kwik streptavidin peroxidase reagent was applied
for 15min and sections were again washed in TBS. The colour was
developed by 15min incubation with DAB solution and sections
were weakly counterstained with haematoxylin. Rat renal tissue
obtained from hypoxic kidneys after 20min ligation of the vessels
were used for positive controls. Normal goat and sheep
immunoglobulin-G was substituted for primary antibody (ab7639
and ab9001, respectively) at a concentration where immunostain-
ing of control slides gave a faint cytoplasmic staining.
Assessment of HIFa and of CA9 expression
The HIF1a and HIF2a proteins were detected using the ESEE 122
(IgG1 Mab; dilution 1:20) and the EP190b (IgG1 Mab; neat)
monoclonal antibodies as we previously described (Talks et al,
2000). For the detection of CA9, we used the alkaline phosphatase/
antialkaline phosphatase (APAAP) procedure and the mouse
monoclonal anti-human CA9 antibody M75 (Pastorek et al,
1994). The immunohistochemical technique, assessment of ex-
pression and identifications of groups of high vs low HIF or CA9
reactivity used have been described in previous studies (Giatro-
manolaki et al, 2001a,b). Assessment was based on the percentage
of cancer cells with strong cytoplasmic/nuclear HIFa reactivity and
of membrane CA9 expression.
Immunohistochemistry for angiogenesis and angiogenic
factor expression
The LDH expression was further analysed in comparison with the
microvessel density and the expression of angiogenic factors
vascular endothelial growth factor (VEGF; VG1 MoAb, University
of Oxford, UK), thymidine phosphorylase (TP; PGF-44c, Uni-
versity of Oxford, UK) and basic-Fibroblast growth factor (bFGF)
and with the bek-bFGF-receptor (Santa Cruz Biotechnology, USA).
The activated VEGF/KDR expressing vascular density was also
assessed using the 11B5 Moab (Texas University, USA). Details on
the immunohistochemistry and assessment of these parameters
have been reported in previous studies of ours (Koukourakis et al,
2000; Giatromanolaki et al, 2000).
Comparison of serum LDH vs immunohistochemistry
In an additional cohort of 33 patients, the LDH serum levels were
prospectively assessed with standard biochemical assays. Serum
samples were taken immediately before bronchoscopic biopsy (11
patients with inoperable stage IIIb NSCLC) or on the day of
operation (22 patients with stage II/IIIa NSCLC who underwent
partial or total pneumonectomy). Lactate dehydrogenase serum
levels were further assessed 8 days after biopsy or surgery,
respectively. Biopsy or surgical material was formalin-fixed and
paraffin-embedded, while LDH immunohistochemistry was per-
formed and assessed, the pathologists being blinded to the results
of LDH biochemistry. In this way, we could assess the correlation
between serum and tissue LDH and, furthermore, we could study
the effect of surgery or biopsy on serum LDH levels. The normal
levels of serum LDH in our laboratory are o450IUl
 1. Lactate
dehydrogenase levels higher than this value were considered as
abnormally high.
Statistical analysis
Statistical analysis and graphs were performed using the GraphPad
Prism
s 2.01 and the Instat
s 3.0 packages (San Diego California
USA, www.graphpad.com). The w
2 t-test, Fisher’s exact t-test or the
unpaired two-tailed t-test was used for testing relationships
LDH in non-small-cell lung cancer
MI Koukourakis et al
878
British Journal of Cancer (2003) 89(5), 877–885 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
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regression analysis was used to test the relationship between
continuous variables. Survival curves were plotted using the
method of Kaplan and Meier, and the log-rank test was used to
determine statistical differences between life tables. A Cox
proportional hazard model was used to assess the effects of
patient and tumour variables on overall survival. All P-values are
two sided and P-values o0.05 were used for significance.
RESULTS
LDH-5 expression patterns
Normal lung cells (bronchial and alveolar) away from the tumour
were unreactive for LDH-5, while positive staining was occasion-
ally noted in normal lung adjacent to the tumour. Chondrocytes of
entrapped cartilage showed nuclear patterns of expression. The
same patterns of staining were obtained with both antibodies used.
Immunohistochemical expression of LDH-5 in cancer cells
revealed both cytoplasmic and nuclear staining patterns. Nuclear
expression was usually accompanied by strong cytoplasmic
expression of LDH-5, while predominantly cytoplasmic expression
was noted in a subset of tumours (Figure 1a,b). Linear regression
analysis between the percentage of cells with LDH-5 expression
obtained with the ab9002 and ab7639 showed a highly significant
correlation (Po0.0001, r¼0.92). All subsequent analyses per-
formed were based on the results obtained with the ab9002 (anti-
human LDH-5). The median percentage of cells with cytoplasmic
LDH-5 expression was 80 (range 0–100; mean 68, s.d. 31). The
median percentage of cancer cells with nuclear LDH expression was
10 (0–100; mean 30, s.d. 37). Linear regression analysis revealed a
highly significant association between the percentage of cells with
cytoplasmic and with nuclear expression (Po0.0001, r¼0.64).
Stroma fibroblasts and vessels were also stained for LDH-5 in 24
out of 112 of the cases analysed, the patterns being predominantly
cytoplasmic and to a lesser extent nuclear. In all these 24 cases,
extensive cancer cell LDH-5 expression was also present. These
staining patterns were obtained with both antibodies used.
Definition of cutoff points
Cases with cytoplasmic LDH-5 reactivity higher than the median
(480%) were grouped as bearing high LDH-5 reactivity (45 cases).
As this cutoff point was very high due to the frequent and
abundant LDH-5 overexpression in NSCLC, the remaining cases
were divided into two groups of low (0–50%; 47 cases) and
medium (51–80%; 30 cases) LDH-5 reactivity.
Using the median percentage of cells with nuclear patterns of
LDH expression,two groups of cases with low vs high LDH-5
nuclear reactivity were defined (low: 0–10% of cells with nuclear
LDH-5 expression, 59 cases; high: 410% of cells with nuclear
LDH-5 expression, 53 cases).
Lactate dehydrogenase association with histopathological
variables
No association of cytoplasmic LDH-5 expression with histology
(adenocarcinomas vs squamous cell carcinomas) or histological
differentiation was noted. High cytoplasmic LDH-5 expression was
more frequent in advanced T-stage (P¼0.10) and nodal involve-
ment (P¼0.15), but the difference was not statistically significant.
Expression of LDH-5 was independent of the degree of necrosis.
Similarly, nuclear patterns of LDH-5 expression did not relate to
any of the histopathological variables examined.
Lactate dehydrogenase association with HIFas and CA9
Linear regression analysis between the percentage of cells with
cytoplasmic LDH-5 expression and the percentage of cells positive
for HIF1a and HIF2a revealed a significant positive correlation
(Po0.0001, r
2¼0.41 and P¼0.03, r
2¼0.20, respectively). No
association with CA9 expression was noted (P¼0.72, r¼0.03).
Similar analysis using the percentage of cells with nuclear LDH
reactivity did not show any association.
Using categorical variable analysis, high cytoplasmic and high
nuclear LDH-5 expression were significantly linked with high
HIF1a expression, but not with HIF2a or CA9 expression (Table 1).
A B
Figure 1 (A) A shows a squamous cell lung carcinoma with nuclear and cytoplasmic LDH-5 overexpression and (B) a lung adenocarcinoma with
predominantly cytoplasmic reactivity.
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Using LDH-5 and all angiogenic parameters as continuous
variables, linear regression analysis showed a significant associa-
tion of cytoplasmic (but not of nuclear) LDH-5 with most of the
angiogenic factors, but not with microvessel density (Table 2).
Categorical variable analysis (using groups as defined in pre-
viously reported studies (Koukourakis et al, 2000; Giatromanolaki
et al, 2000) showed similar results (data not shown). Briefly, a
significant association of high LDH-5 cytoplasmic expression with
VEGF cytoplasmic expression was noted (P¼0.01). Similarly, a
significant association of LDH-5 cytoplasmic expression with bFGF
and bek-bFGF-receptor expression was confirmed (P¼0.004 and
0.05, respectively), while the association with TP expression was
marginal (P¼0.07). The association of LDH-5 nuclear expression
with these variables was less strong and did not reach significance.
Lactate dehydrogenase-5 expression was not associated with
microvessel density or the activated VEGF/KDR microvessel
density (aMVD).
Association of HIFas with VEGF and CA9
The association among these variables in NSCLCs, in the same
material used in the present study, has been extensively analysed
in two previous studies (Giatromanolaki et al, 2001a, b). Briefly,
VEGF is directly related to HIF1a and HIF2a but not with CA9. A
marginal, not significant, association between CA9 expression and
HIF1a was also noted (data not shown).
LDH-5 and overall survival
Figure 2 shows the Kaplan–Meier overall survival curves stratified
for cytoplasmic LDH-5 (low vs medium vs high) and nuclear (low
vs high) LDH-5 expression. A significantly poorer survival was
noted in the group of patients with high LDH-5 cytoplasmic and
high LDH-5 nuclear reactivity (P¼0.03 and 0.02, respectively).
In multivariate analysis using a model that comprised the T-, N-
stage, CA9 and HIFas expression, LDH-5 expression did not reach
an independent prognostic significance (P¼0.15, t-ratio¼1.44),
probably due to the close association with HIFas and angiogenic
factor expression. However, the prognostic usefulness of LDH-5 as
a marker is better revealed in double stratification with HIFas.
Overexpression of LDH-5 is a marker of a functional HIFa
pathway, and as such LDH-5 could enhance the prognostic
usefulness of HIFas. Indeed, HIF1a and 2a overexpression related
to poor overall survival only when LDH-5 was also overexpressed
(whether cytoplasmic or nuclear). Figures 3a and b show the
Kaplan–Meier survival curves according to HIF1a and 2a
expression, respectively, stratified for nuclear LDH-5 reactivity.
In multivariate analysis, the combination of nuclear LDH-5 and
HIF2a expression showed a very strong independent prognostic
relevance. Table 3 shows the multivariate analysis in three
statistical models and the relative risk.
An additional survival analysis was performed by stratifying for
LDH-5 nuclear and CA9 overexpression. Again, upregulation of
either of the enzymes was linked with poor survival (Figure 4).
Serum LDH levels vs immunohistochemistry
The median value of LDH serum levels was 410IUl
 1 (range 234–
1294). In all, 20 out of 33 patients had LDH serum levels lower than
the upper normal LDH value (450IUl
 1), while in 13 the LDH
serum levels were higher than the normal. Linear regression
analysis between the serum LDH levels and the percentage of
cancer cells with cytoplasmic (and/or nuclear) LDH-5 reactivity
showed a statistically significant correlation (P¼0.01, r¼0.41;
Figure 5). Categorical analysis showed , however, that the results
from the two methods are not overlapping as 10 out of 20 patients
with high LDH-5 tissue reactivity had LDH serum levels lower than
the highest normal value (Figure 5). The tumour stroma LDH-5
immunohistochemical reactivity was not related with serum LDH
levels (data not shown).
In accordance with the previously reported results, in this series
of 33 patients a significant association of tissue LDH-5 expression
with HIF1a was recorded, while serum LDH levels were not
significantly related to HIF1a overexpression (data not shown).
At eight days following biopsy, the mean serum LDH levels were
unchanged (5927300 vs 6367317; P¼0.78), while a statistically
significant drop was noted in patients who underwent surgery
(5277329 vs 3697117; P¼0.03). The sharp drop of LDH serum
levels was more evident in patients with high preoperative LDH
serum levels (P¼0.0004); Figure 6.
DISCUSSION
Lactate dehydrogenase, assessed in the sera of cancer patients, is
considered as a marker of poor postoperative outcome in a large
Table 1 Association of LDH cytoplasmic and nuclear expression with HIF1a, HIF2a and CA9 expression
LDH cytoplasmic LDH nuclear
Low Medium High P-value Low High P-value
HIF1a
Low 24 10 8 o0.0001 28 14 0.03
high 13 20 37 31 39
HIF2a
Low 22 14 18 0.21 31 23 0.35
high 15 16 27 28 30
CA9
Low 22 17 24 0.85 35 28 0.56
high 15 13 21 24 25
Table 2 Linear regression analysis of LDH cytoplasmic expression with
microvessel density and angiogenic factor and receptors
P-value r-value
MVD 0.65 0.04
aMVD 0.23 0.12
VEGF 0.01 0.22
bFGF 0.0002 0.35
bFGFr 0.01 0.23
TP 0.04 0.20
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yspectrum of neoplastic diseases including pancreatic carcinoma
(Tas et al, 2001a), osteosarcoma (Ferrari et al, 2001), renal and
testicular carcinoma (Motzer et al, 1999; vonEyben et al, 2001) and
melanoma (Hauschild et al, 1999). An increased metastatic
potential of nasopharyngeal carcinomas in patients with high
LDH serum levels has also been reported (Cheng et al, 1998).
Furthermore, clinicopathological studies suggest that high LDH
serum levels are linked with radioresistance of head–neck cancer
(Brizel et al, 2001), brain primary and metastatic tumours
(Kushner et al, 2001; Lutterbach et al, 1999; Lagerwaard et al,
1999). Elevated LDH serum levels are also linked with resistance to
and high rate of relapse after chemotherapy in lymphomas (Kondo
et al, 2001; Wilder et al, 2001), breast and ovarian cancer (Ryberg
et al, 2001; Yuce et al, 2001), as well as in small cell lung cancer
(Argiris et al, 2001; Tas et al, 2001b).
The ominous prognostic significance of serum LDH in
malignancy could be attributed to several reasons: (i) increased
LDH activity results in lactic acid production and acidification of
the extracellular water space, which is a very common feature in
cancer (Vaupel et al, 1989; Stubbs et al, 2000). Acidic extracellular
pH has been shown to activate gelatinase activity and production
of cathepsin D, which contribute to an increased cancer cell
invasive ability (Rozhin et al, 1994; Martinez-Zagulian et al, 1996).
Activation of macrophage-mediated angiogenesis by lactate may
also facilitate metastasis (Jensen et al, 1986; Zabel et al, 1996;
Murray and Wilson, 2001). Moreover, low pH protects mitochon-
dria from oxidative stress and may account for increased
resistance of cancer cells to hypoxia-induced apoptosis (Bronk
and Gores, 1991; Nemoto et al, 2000); (ii) increased LDH
production by cancer cells can be a direct marker of intratumoral
hypoxia (Firth et al, 1995), and therefore a strong marker of
tumour resistance to radiotherapy and some chemotherapeutic
agents; (iii) as LDH-5 is transcriptionally regulated by HIFas, high
LDH serum levels may reflect an upregulated HIF-molecular
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Figure 2 Kaplan–Meier overall survival curves stratified for cytoplasmic
(A) and nuclear (B) LDH-5 reactivity.
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Figure 3 Kaplan–Meier overall survival curves following double
stratification for nuclear LDH-5 reactivity and HIF1a (A) or HIF2a (B)
overexpression.
Table 3 Multivariate analysis of the impact of combined expression of HIFas and the nuclear expression of
LDH-5 on death events in three statistical models
Model I Model II Model III
Parameter t-ratio P-value t-ratio P-value t-ratio P-value
HIF1a/LDH-5 0.46 0.64 — — — —
HIF2a/LDH-5 2.53 0.01 2.79 0.006 3.02 0.003
CA9 1.03 0.30 1.07 0.28 — —
N-stage 2.93 0.004 2.90 0.004 3.01 0.003
T-stage 1.86 0.06 1.81 0.07 2.54 0.01
Grade 0.43 0.66 0.37 0.70 — —
Histology 1.13 0.26 1.20 0.23 — —
VEGF 0.17 0.85 0.15 0.87 — —
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1998). Hypoxia inducible factor stabilisation that occurs due to
hypoxia or genetic mutations results in the overexpression of a
variety of proteins linked to angiogenesis/metastasis, glycolysis
and resistance to apoptosis (Semenza, 1998; Akakura et al, 2001;
Harris, 2002). In that way, high serum LDH levels may be an
indirect marker of HIF-dependent tumour aggressiveness and
resistance to cytotoxic regimens (Aebersold et al, 2001; Koukour-
akis et al, 2001b; Koukourakis et al, 2002).
Serum levels, however, are unlikely to reflect adequately the
intratumoral LDH activity, as the bulk of the neoplastic disease or
individual variations of LDH clearance are strong confounding
factors. On the other hand, biochemical assessment of LDH from
tumour tissue extracts (Beasley et al, 2000) give measurements that
strongly vary with the amount of the nonmalignant cellular
component (stromal and reactive cells) or even with the extent of
necrotic tissue that composes the tumour sample used to obtain
tissue extracts. In the present study, we showed that immunohis-
tochemical assessment of LDH-5 allows (i) the differential
assessment of LDH-5 production by cancer and noncancerous
cells of the tumours, (ii) the intensity of LDH-5 activity within
cancer cells and (iii) the identification of subcellular patterns of
LDH-5 localisation that could be of biological relevance. Im-
munohistochemistry, therefore, allows the characterisation of the
individual cancer cell LDH activity, which cannot be adequately
predicted by serum LDH levels or tissue LDH biochemistry.
Indeed, comparative analysis of serum LDH levels and immuno-
histochemistry showed a positive trend and the results between the
two methods were not overlapping.
The patterns of LDH-5 subcellular expression by cancer cells
were cytoplasmic with a varying degree of nuclear localisation.
Lactate dehydrogenase is well known to reside in both the
cytoplasm and nuclei (Reddy and Shukla, 2001). In the majority
of cases, the tumoral stroma (fibroblasts, vessels and reactive cells)
was unreactive for LDH-5, while in a minority of cases extensive
cytoplasmic expression of LDH-5 in stromal cells accompanied
LDH-5 overexpression by cancer cells. This finding, together with
the observation that serum LDH levels correlated positively with
cancer cell LDH-5 reactivity but not with stroma reactivity,
strongly suggests that high LDH levels found in the sera of cancer
patients are mainly of cancer cell origin, while the contribution of
stroma cells is minimal. The rapid drop of LDH serum levels 8
days following surgery further confirms that the excess serum LDH
levels found in a subset of NSCLC patients is of tumour origin.
We further assessed whether the LDH-5 expression status by
cancer cells relates to any of the histological tumour character-
istics. In a previous study by Mall et al (2002), serum LDH levels
correlated with advanced stage in small cell lung cancer, and
similar findings have been reported for ovarian cancer (Yuce et al,
2001). Poor differentiation has also been linked with high LDH
levels in squamous cell HNC (Ross et al, 2000). An increased
incidence of metastasis in patients with Ewing’s sarcoma or
nasopharyngeal carcinoma has also been reported to relate with
high serum LDH levels (Cheng et al, 1998; Bacci et al, 2000). In our
study, overexpression of LDH-5 by cancer cells was more frequent
in large tumours or in cases with node involvement, but this was
not statistically significant. Tumour histological type and differ-
entiation or the extent of necrosis were not related to LDH-5
expression.
A strong significant association of LDH-5 overexpression with
HIF1a and to a lesser extent with HIF2a was noted, which is in full
accordance with studies showing that LDH-5 is transcriptionally
regulated by the HIFas (Semenza et al, 1996; Ebert and Bunn,
1998). Lactate dehydrogenase-5 expression patterns were similar to
that observed in HIFa immunostaining, in that reactivity when
present was diffuse and not around necrotic areas (Giatromanolaki
et al, 2001b). This is in direct contrast with the expression of CA9,
where its expression was strongly related with the extent of
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ynecrosis and most often localised in cancer cell layers proximal to
necrotic areas (Giatromanolaki et al, 2001a). Lactate dehydrogen-
ase-5 was not linked with CA9 expression. Although CA9 gene
expression is HIFa regulated (Wykoff et al, 2001), the threshold of
hypoxia necessary for the transcription of CA9 or LDH-5 may
differ (Giatromanolaki et al, 2001a), which could explain the lack
of association between LDH and CA9 expression as well as the
discordant relation of these proteins with necrosis. Nevertheless,
HIFas and LDH-5 are additionally regulated by oncogenes and
cytokines, which may account for their more diffuse expression
than CA9.
In some tumours, overexpression of HIF1a was not accom-
panied by LDH-5 overexpression. This could show a defective
HIF1a pathway, or tumour and gene polymorphism differences in
the regulation of individual genes. Alterations on the expression or
function of molecules involved in the HIF-DNA binding may exist
(Ebert and Bunn, 1998; Ema et al, 1999). On the other hand, the
overexpression of LDH in a minority of cases with no HIFa
reactivity may indicate hypoxia independent pathways of LDH-5
transcriptional regulation, for example, c-myc activation (Shim
et al, 1997).
Combined assessment of HIF1a with LDH-5 expression could
therefore predict for an intact or defective HIF pathway. This
hypothesis was tested in the survival analysis performed in the
present study. In a previous study we showed that HIFas
overexpression is linked with poor postoperative outcome in
NSCLC. In the present study LDH-5 overexpression was similarly
linked with poor prognosis. Double stratification analysis showed
that HIF1a and HIF2a overexpression defined poor prognosis only
when LDH-5 was overexpressed. This observation suggests that
combined HIFa and LDH-5 assessment is a more potent
prognostic tool, reflecting the downstream programme regulated
by HIF as being a profile mediating poor prognosis. Further
analysis of LDH-5 together with CA9 expression revealed that
overexpression of either of the enzymes is independently linked
with poor survival. Acidification of the tumour environment
expected in both conditions explains in part such an aggressive
tumour behaviour (Rozhin et al, 1994; Martinez-Zagulian et al,
1996; Stubbs et al, 2000).
We further examined the association of LDH-5 expression with
angiogenesis and activation of various angiogenic pathways.
Although LDH was not related to the microvessel density, a
significant association of LDH-5 with VEGF, bFGF and to TP
expression was noted. Vascular endothelial growth factor coex-
pression with LDH was expected not only due to the HIFa
dependent regulation of both molecules, but also due to a direct
effect of acidosis on VEGF upregulation (Fukumura et al, 2001; Shi
et al, 2001). In two previous studies, using the same material
herein analysed, we showed that VEGF is directly associated with
the expression of HIF1a and HIF2a, while CA9 expression was
marginally associated with HIF1a (Giatromanolaki et al, 2001b,c).
A significant association between LDH and VEGF levels in the
pleural fluid of patients with various diseases has been reported
(Cheng et al, 1999). The strong association of LDH with bFGF
activated pathway, however, may be due to HIF-independent
reasons. For example, acidification of the tumour environment by
lactate may account for bFGF overexpression (D’Arcangelo et al,
2000). On the other hand, a direct effect of bFGF on LDH cellular
levels has been recently shown by Riera et al (2002).
The present study provides the basis for the immunohisto-
chemical assessment of LDH in tumoral tissues. Lactate
dehydrogenase immunohistochemistry can better predict the
cancer cell LDH activity than serum LDH or biochemistry on
tissue extracts. Lactate dehydrogenase cancer cell overexpression
related to HIFa overexpression, and the abundant expression of
various angiogenic factors. While LDH cancer cell expression
represents an important tool to predict aggressive tumour
behavior, it becomes a more powerful prognostic tool when
combined with HIFa expression. Downregulated LDH on the
background of HIFa overexpression allows the identification of a
subgroup of tumours with a less aggressive pattern of gene
expression regulated by HIF. This may prove to be of importance
as therapeutic strategies targeting HIF activity become available
(Kung et al, 2000). As endogenous markers of hypoxia have
recently focused attention as predictors of response to
radiotherapy and chemotherapy (Aebersold et al, 2001; Koukour-
akis et al, 2001a,b, 2002), combined HIF/LDH analysis may
become of value. The expression of LDH was independent of
another enzyme involved in tumour acidity and hypoxia, namely
CA9, although expression of either of the enzymes related to an
ominous prognosis. It seems that LDH, CA9 and HIFas
immunohistochemistry can reliably predict tumour aggressiveness
related to acidity and hypoxia, although this requires further
investigation.
REFERENCES
Aebersold DM, Burri P, Beer KT, Laissue J, Djonov V, Greiner RH, Semenza
GL (2001) Expression of hypoxia-inducible factor-1alpha: a novel
predictive and prognostic parameter in the radiotherapy of orophar-
yngeal cancer. Cancer Res 61: 2911–2916
Akakura N, Kobayashi M, Horiuchi I, Suzuki A, Wang J, Chen J, Niizeki H,
Kawamura K, Hosokawa M, Asaka M (2001) Constitutive expression of
hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant
to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res
61: 6548–6554
Argiris A, Murren JR (2001) Staging and clinical prognostic factors for
small-cell lung cancer. Cancer J 7: 437–447
Bacci G, Ferrari S, Bertoni F, Rimondini S, Longhi A, Bacchini P,
Forni C, Manfrini M, Donati D, Picci P (2000) Prognostic factors in
nonmetastatic Ewing’s sarcoma of bone treated with adjuvant che-
motherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J
Clin Oncol 18: 4–11
Beasley NJ, Leek R, Alam M, Turley H, Cox GJ, Gatter K, Millard P, Fuggle
S, Harris AL (2000) Hypoxia-inducible factors HIF-1alpha and HIF-
2alpha in head and neck cancer relationship to tumor biology and
treatment outcome in surgically resected patients. Cancer Res
62: 2493–2497
Brizel DM, Schroeder T, Scher RL, Walenta S, Clough RW, Dewhirst MW,
Mueller-Klieser W (2001) Elevated tumor lactate concentrations predict
for an increased risk of metastases in head-and-neck cancer. Int J Radiat
Oncol Biol Phys 51: 349–353
Bronk SF, Gores GJ (1991) Acidosis protects against lethal oxidative injury
of liver sinusoidal endothelial cells. Hepatology 14: 150–157
Brown JM (2002) Tumor microenvironment and the response to anticancer
therapy. Cancer Biol Ther 1: 453–458
Cheng D, Rodriguez RM, Perkett EA, Rogers J, Bienvenu G, Lappalainen U,
Light RW (1999) Vascular endothelial growth factor in pleural fluid.
Chest 116: 760–765
Cheng SH, Jian JJ, Tsai SY, Chan KY, Yen LK, Chu NM, Tan TD, Tsou MH,
Huang AT (1998) Prognostic features and treatment outcome in
locoregionally advanced nasopharyngeal carcinoma following concur-
rent chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 41:
755–762
D’Arcangelo D, Facchiano F, Barlucchi LM, Melillo G, Illi B, Testolin L,
Gaetano C, Capogrossi MC (2000) Acidosis inhibits endothelial
cell apoptosis and function and induces basic fibroblast growth
factor and vascular endothelial growth factor expression. Circ Res 86:
312–318
Ebert BL, Bunn HF (1998) Regulation of transcription by hypoxia requires a
multiprotein complex that includes hypoxia-inducible factor 1, an
adjacent transcription factor, and p300/CREB binding protein. Mol Cell
Biol 18: 4089–4096
LDH in non-small-cell lung cancer
MI Koukourakis et al
883
British Journal of Cancer (2003) 89(5), 877–885 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yEma M, Hirota K, Mimura J, Abe H, Yodoi J, Sogawa K, Poellinger L, Fujii-
Kuruyama Y (1999) Molecular mechanisms of transcription activation by
HLF and HIF1a in response to hypoxia: their stabilization and redox
signal-induced interaction with CBP/p300. EMBO 18: 1905–1914
Ferrari S, Bertoni F, Mercuri M, Picci P, Giacomini S, Longhi A, Bacci G
(2001) Predictive factors of disease-free survival for non-metastatic
osteosarcoma of the extremity: an analysis of 300 patients treated at the
Rizzoli Institute. Ann Oncol 12: 1145–1150
Firth JD, Ebert BL, Ratcliffe PJ (1995) Hypoxic regulation of lactate
dehydrogenase A Interaction between hypoxia-inducible factor 1 and
cAMP response elements. J Biol Chem 270: 21021–21027
Fukumura D, Xu L, Chen Y, Gohongi T, Seed B, Jain RK (2001) Hypoxia
and acidosis independently up-regulate vascular endothelial growth
factor transcription in brain tumors in vivo. Cancer Res 61: 6020–6024
Giatromanolaki A, Koukourakis MI, Sivridis E, O’Byrne K, Cox G, Thorpe
PE, Gatter KC, Harris AL (2000) Coexpression of MUC1 glycoprotein
with multiple angiogenic factors in non-small cell lung cancer suggests
coactivation of angiogenic and migration pathways. Clin Cancer Res 6:
1917–1921
Giatromanolaki A, Harris AL (2001) Tumour hypoxia, hypoxia signaling
pathways and hypoxia inducible factor expression in human cancer.
Anticancer Res 21: 4317–4324
Giatromanolaki A, Koukourakis MI, Sivridis E, Pastorek J, Wykoff CC,
Gatter KC, Harris AL (2001a) Expression of hypoxia-inducible carbonic
anhydrase-9 relates to angiogenic pathways and independently to poor
outcome in non-small cell lung cancer. Cancer Res 61: 7992–7998
Giatromanolaki A, Koukourakis MI, Sivridis E, Turley H, Talks K, Pezzella
F, Gatter KC, Harris AL (2001b) Relation of hypoxia inducible factor 1
alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/
molecular profile of tumours and survival. Br J Cancer 85: 881–890
Gray LH, Conger AD, Ebert M (1953) The concentration of oxygen
dissolved in tissues at the time of irradiation as a factor in radiotherapy.
Br J Radiol 26: 683
Harris AL (2002) Hypoxia: a key regulatory factor in tumour growth. Nat
Rev Cancer 2: 38–47
Hauschild A, Michaelsen J, Brenner W, Rudolph P, Glaser R, Henze E,
Christophers E (1999) Prognostic significance of serum S100B detection
compared with routine blood parameters in advanced metastatic
melanoma patients. Melanoma Res 9: 155–161
Holbrook JJ, Liljas A, Steindel SJ, Rossman MG (1975) Lactate dehydro-
genase. In The Enzymes Boyer PD (ed.), , Vol. XI, 3rd edn, pp. 191–292.
New York: Academic Press
Jensen JA, Hunt TK, Scheuenstuhl H, Banda MJ (1986) Effect of lactate,
pyruvate, and pH on secretion of angiogenesis and mitogenesis factors
by macrophages. Lab Invest 54: 574–578
Kondo E, Ogura M, Kagami Y, Taji H, Miura K, Takeuchi T, Maeda S,
Asakura S, Suzuki R, Nakamura S, Morishima Y (2001) Assessment of
prognostic factors in follicular lymphoma patients. Int J Hematol 73:
363–368
Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos K, Pastorek J,
Wykoff CC, Gatter KC, Harris AL (2001a) Hypoxia-regulated carbonic
anhydrase-9 (CA9) relates to poor vascularization and resistance of
squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer
Res 7: 3399–3403
Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos C, Turley H,
Talks K, Gatter KC, Harris AL (2002) Hypoxia-inducible factor (HIF1A
and HIF2A), angiogenesis, and chemoradiotherapy outcome of squa-
mous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys 53: 1192–
1202
Koukourakis MI, Giatromanolaki A, Skarlatos J Corti L, Blandamura S,
Piazza M, Gatter KC, Harris AL (2001b) Hypoxia inducible factor (HIF-
1a and HIF-2a) expression in early esophageal cancer and response to
photodynamic therapy and radiotherapy. Cancer Res 61: 1830–1832
Koukourakis MI, Giatromanolaki A, Thorpe PE, Brekken RA, Sivridis E,
Kakolyris S, Georgoulias V, Gatter KC, Harris AL (2000) Vascular
endothelial growth factor/KDR activated microvessel density versus
CD31 standard microvessel density in non-small cell lung cancer. Cancer
Res 60: 3088–3095
Kung AL, Wang S, Klco JM, Kaelin WG, Livingston DM (2000) Suppression
of tumor growth through disruption of hypoxia-inducible transcription.
Nat Med 6: 1335–1340
Kushner BH, Wolden S, LaQuaglia MP, Kramer K, Verbel D, Heller G,
Cheung NK (2001) Hyperfractionated low-dose radiotherapy for high-
risk neuroblastoma after intensive chemotherapy and surgery. J Clin
Oncol 19: 2821–2828
Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens PE,
Schmitz PI (1999) Identification of prognostic factors in patients with
brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys
43: 795–803
Lutterbach J, Weigel P, Guttenberger R, Hinkelbein W (1999) Accelerated
hyperfractionated radiotherapy in 149 patients with glioblastoma multi-
forme. Radiother Oncol 53: 49–52
Mall JW, Schwenk W, Philipp AW, Meyer-Kipker C, Mall W, Muller J,
Pollmann C (2002) Serum vascular endothelial growth factor levels
correlate better with tumour stage in small cell lung cancer than
albumin, neuron-specific enolase or lactate dehydrogenase. Respirology
7: 99–102
Martinez-Zaguilan R, Seftor EA, Seftor RE, Chu YW, Gillies RJ, Hendrix MJ
(1996) Acidic pH enhances the invasive behavior of human melanoma
cells. Clin Exp Metast 14: 176–186
Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999)
Survival and prognostic stratification of 670 patients with advanced renal
cell carcinoma. J Clin Oncol 17: 2530–2540
Murray B, Wilson DJ (2001) A study of metabolites as intermediate
effectors in angiogenesis. Angiogenesis 4: 71–77
Nemoto S, Takeda K, Yu ZX, Ferrans VJ, Finkel T (2000) Role for
mitochondrial oxidants as regulators of cellular metabolism. Mol Cell
Biol 20: 7311–7318
Opavsky R, Pastorekova S, Zelnik V, Gibadulinova A, Stanbridge EJ, Zavada
J, Kettmann R, Pastorec J (1996) Human MN/CA9 gene, a novel member
of the carbonic anhydrase family: structure and exon to protein domain
relationships. Genomics 33: 480–487
Pastorek P, Pastorekova S, Callebaut I, Mornon JP, Zelnik V, Opavsky R,
Zat’ovicova M, Liao S, Portetelle D, Stanbridge EJ, Zavada J, Burny A,
Kettmann R (1994) Cloning and characterization of MN, a human tumor-
associated protein with a domain homologous to carbonic anhydrase and
a putative helix-loop-helix DNA binding segment. Oncogene 9: 2877–
2888
Reddy MA, Shukla SD (2001) Nuclear activation and translocation of
mitogen-activated protein kinases modulated by ethanol in embryonic
liver cells. Biochim Biophys Acta 1497: 271–278
Riera MF, Meroni SB, Schteingart HF, Pellizzari EH, Cigorraga SB (2002)
Regulation of lactate production and glucose transport as well as of
glucose transporter 1 and lactate dehydrogenase A mRNA levels by basic
fibroblast growth factor in rat Sertoli cells. J Endocrinol 173: 335–343
Rofstad EK (2000) Microenvironment-induced cancer metastasis. Int J
Radiat Biol 76: 589–605
Rozhin J, Sameni M, Ziegler G, Sloane BF (1994) Pericellular pH affects
distribution and secretion of cathepsin B in malignant cells. Cancer Res
54: 6517–6525
Ross CD, Gomaa MA, Gillies E, Juengel R, Medina JE (2000) Tumor grade,
microvessel density, and activities of malate dehydrogenase, lactate
dehydrogenase, and hexokinase in squamous cell carcinoma. Otolaryngol
Head Neck Surg 122: 195–200
Ryberg M, Nielsen D, Osterlind K, Skovsgaard T, Dombernowsky P (2001)
Prognostic factors and long-term survival in 585 patients with metastatic
breast cancer treated with epirubicin-based chemotherapy. Ann Oncol
12: 81–87
Semenza GL (1998) Hypoxia-inducible factor 1: master regulator of O2
homeostasis. Curr Opin Genet Dev 8: 588–594
Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P,
Giallongo A (1996) Hypoxia response elements in the aldolase A, enolase
1, and lactate dehydrogenase A gene promoters contain essential binding
sites for hypoxia-inducible factor 1. J Biol Chem 271: 32529–32537
Shi Q, Le X, Wang B, Abbruzzese JL, Xiong Q, He Y, Xie K (2001)
Regulation of vascular endothelial growth factor expression by acidosis
in human cancer cells. Oncogene 20: 3751–3756
Shim H, Dolde C, Lewis BC, Wu CS, Dang G, Jungmann RA, Dalla-Favera R,
Dang CV (1997) c-Myc transactivation of LDH-A: implications for tumor
metabolism and growth. Proc Natl Acad Sci U S A. 94: 6658–6663
Stubbs M, McSheehy PM, Griffiths JR, Bashford CL (2000) Causes and
consequences of tumour acidity and implications for treatment. Mol Med
Today 6: 15–19
Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris
AL (2000) The expression and distribution of the hypoxia-inducible
factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers,
and tumor-associated macrophages. Am J Pathol 57: 411–421
Tas F, Aydiner A, Demir C, Topuz E (2001b) Serum lactate dehydrogenase
levels at presentation predict outcome of patients with limited-stage
small-cell lung cancer. Am J Clin Oncol 24: 376–378
LDH in non-small-cell lung cancer
MI Koukourakis et al
884
British Journal of Cancer (2003) 89(5), 877–885 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yTas F, Aykan F, Alici S, Kaytan E, Aydiner A, Topuz E (2001a) Prognostic
factors in pancreatic carcinoma: serum LDH levels predict survival in
metastatic disease. Am J Clin Oncol 24: 547–550
Vaupel P, Kallinowski F, Okunieff P (1989) Blood flow, oxygen and nutrient
supply, and metabolic microenvironment of human tumors: a review.
Cancer Res 49: 6449–6465
Vaupel P, Thews O, Hoeckel M (2001) Treatment resistance of solid tumors:
role of hypoxia and anemia. Med Oncol 18: 243–259
von Eyben FE, Madsen EL, Blaabjerg O, Petersen PH, von der Maase H,
Jacobsen GK, Rorth M (2001) Serum lactate dehydrogenase isoenzyme 1
and relapse in patients with nonseminomatous testicular germ cell
tumors clinical stage I. Acta Oncol 40: 536–540
Wilder RB, Rodriguez MA, Ha CS, Pro B, Hess MA, Cabanillas F, Cox JD
(2001) Bulky disease is an adverse prognostic factor in patients treated
with chemotherapy comprised of cyclophosphamide, doxorubicin,
vincristine, and prednisone with or without radiotherapy for aggressive
lymphoma. Cancer 91: 2440–2446
Wykoff CC, Beasley NJP, Watson PH, Turner KJ, Pastorek J, Wilson GD,
Turley H, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL (2001) Hypoxia
inducible regulation of tumor associated carbonic anhydrases. Cancer
Res 60: 7075–7083
Yamagata M, Hasuda K, Stamato T, Tannock IF (1998) The contribution of
lactic acid to acidification of tumours: studies of variant cells lacking
lactate dehydrogenase. Br J Cancer 77: 1726–1731
Yuce K, Baykal C, Genc C, Al A, Ayhan A (2001) Diagnostic and prognostic
value of serum and peritoneal fluid lactate dehydrogenase in epithelial
ovarian cancer. Eur J Gynaecol Oncol 22: 228–232
Zabel DD, Feng JJ, Scheuenstuhl H, Hunt TK, Hussain MZ (1996)
Lactate stimulation of macrophage-derived angiogenic activity is
associated with inhibition of poly(ADP-ribose) synthesis. Lab Invest
74: 644–649
Zaman K, Ryu H, Hall D, O’Donovan K, Lin KI, Miller MP, Marquis JC,
Baraban JM, Semenza GL, Ratan RR (1999) Protection from oxi-
dative stress-induced apoptosis in cortical neuronal cultures by
iron chelators is associated with enhanced DNA binding of hypoxia-
inducible factor-1 and ATF-1/CREB and increased expression of
glycolytic enzymes, p21(waf1/cip1), and erythropoietin. J Neurosci 19:
9821–9830
LDH in non-small-cell lung cancer
MI Koukourakis et al
885
British Journal of Cancer (2003) 89(5), 877–885 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y